

Ivermectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.1	03.02.2025	1204361-00026	Date of first issue: 09.01.2017

SECTION 1: IDENTIFICATION

Product name : Ivermectin Liquid Formulation

Manufacturer or supplier's details

Company : Intervet Australia Pty Limited (trading as MSD Animal Health)

Address : 91-105 Harpin Street
Bendigo 3550, Victoria Australia

Telephone : 1 800 033 461

Emergency telephone number : Poisons Information Centre: Phone 13 11 26

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION**GHS Classification**

Skin corrosion/irritation : Category 2

Serious eye damage/eye irritation : Category 2A

Reproductive toxicity : Category 1B

Specific target organ toxicity - single exposure (Oral) : Category 2 (Central nervous system)

Specific target organ toxicity - single exposure : Category 3

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Central nervous system)

GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H315 Causes skin irritation.

Ivermectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.1	03.02.2025	1204361-00026	Date of first issue: 09.01.2017

H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
H360D May damage the unborn child.
H371 May cause damage to organs (Central nervous system) if swallowed.
H373 May cause damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.

Precautionary statements**Prevention:**

P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe mist or vapours.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P271 Use only outdoors or in a well-ventilated area.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P302 + P352 IF ON SKIN: Wash with plenty of water.
P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.
P332 + P313 If skin irritation occurs: Get medical advice/ attention.
P337 + P313 If eye irritation persists: Get medical advice/ attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Oils, sesame	8008-74-0	>= 60 -<= 100
N-Methyl-2-pyrrolidone	872-50-4	>= 10 -< 20

Ivermectin Liquid Formulation

Version 9.1	Revision Date: 03.02.2025	SDS Number: 1204361-00026	Date of last issue: 06.07.2024 Date of first issue: 09.01.2017
----------------	------------------------------	------------------------------	---

Ivermectin	70288-86-7	>= 1 -< 10
------------	------------	------------

SECTION 4. FIRST AID MEASURES

- | | | |
|---|---|---|
| General advice | : | In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice. |
| If inhaled | : | If inhaled, remove to fresh air.
Get medical attention. |
| In case of skin contact | : | In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse. |
| In case of eye contact | : | In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention. |
| If swallowed | : | If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
Never give anything by mouth to an unconscious person. |
| Most important symptoms and effects, both acute and delayed | : | Causes skin irritation.
Causes serious eye irritation.
May cause respiratory irritation.
May damage the unborn child.
May cause damage to organs if swallowed.
May cause damage to organs through prolonged or repeated exposure if swallowed. |
| Protection of first-aiders | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| Notes to physician | : | Treat symptomatically and supportively. |

SECTION 5. FIREFIGHTING MEASURES

- | | | |
|---------------------------------------|---|--|
| Suitable extinguishing media | : | Water spray
Alcohol-resistant foam
Carbon dioxide (CO ₂)
Dry chemical |
| Unsuitable extinguishing media | : | None known. |
| Specific hazards during fire-fighting | : | Exposure to combustion products may be a hazard to health. |
| Hazardous combustion products | : | Carbon oxides
Nitrogen oxides (NO _x) |

Ivermectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.1	03.02.2025	1204361-00026	Date of first issue: 09.01.2017

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Hazchem Code : •3Z

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.
Do not breathe mist or vapours.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.

Ivermectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
9.1	03.02.2025	1204361-00026	06.07.2024
			Date of first issue: 09.01.2017

- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
- Keep container tightly closed.
- Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers.
- Do not eat, drink or smoke when using this product.
- Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
- When using do not eat, drink or smoke.
- Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labelled containers.
- Store locked up.
- Keep tightly closed.
- Keep in a cool, well-ventilated place.
- Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
- Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Oils, sesame	8008-74-0	TWA (Mist)	10 mg/m ³	AU OEL
N-Methyl-2-pyrrolidone	872-50-4	TWA	25 ppm 103 mg/m ³	AU OEL
Further information: Skin absorption				
		STEL	75 ppm 309 mg/m ³	AU OEL
Further information: Skin absorption				
Ivermectin	70288-86-7	TWA	30 µg/m ³ (OEB 3)	Internal
Further information: Skin				
		Wipe limit	300 µg/100 cm ²	Internal

Ivermectin Liquid Formulation

Version 9.1 Revision Date: 03.02.2025 SDS Number: 1204361-00026 Date of last issue: 06.07.2024
 Date of first issue: 09.01.2017

Biological occupational exposure limits

Components	CAS-No.	Control parameters	Biological specimen	Sampling time	Permissible concentration	Basis
N-Methyl-2-pyrrolidone	872-50-4	5-Hydroxy-N-methyl-2-pyrrolidone	Urine	End of shift (As soon as possible after exposure ceases)	100 mg/l	ACGIH BEI

Engineering measures : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
 Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
 Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Combined particulates and organic vapour type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.
 If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
 Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.
 Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
 Use appropriate degowning techniques to remove potentially contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : liquid

Colour : light yellow

Ivermectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.1	03.02.2025	1204361-00026	Date of first issue: 09.01.2017

Odour	:	characteristic
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	> 100 °C
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	0.90 - 0.92 g/cm ³
Solubility(ies)		
Water solubility	:	insoluble
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available

Ivermectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.1	03.02.2025	1204361-00026	Date of first issue: 09.01.2017

Particle characteristics
Particle size : Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : Can react with strong oxidizing agents.
Conditions to avoid : None known.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Exposure routes : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:**Oils, sesame:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

N-Methyl-2-pyrrolidone:

Acute oral toxicity : LD50 (Rat): 4,150 mg/kg
Method: OECD Test Guideline 401
Remarks: The test was conducted equivalent or similar to guideline

Acute inhalation toxicity : LC50 (Rat): > 5.1 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 403
Remarks: The test was conducted according to guideline

Ivermectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.1	03.02.2025	1204361-00026	Date of first issue: 09.01.2017

Acute dermal toxicity : LD50 (Rat): > 5,000 mg/kg
Method: OECD Test Guideline 402
Remarks: The test was conducted equivalent or similar to guideline

Ivermectin:

Acute oral toxicity : LD50 (Rat): 50 mg/kg

LD50 (Mouse): 25 mg/kg

LD50 (Monkey): > 24 mg/kg
Target Organs: Central nervous system
Symptoms: Vomiting, Dilatation of the pupil
Remarks: No mortality observed at this dose.

Acute inhalation toxicity : LC50 (Rat): 5.11 mg/l
Exposure time: 1 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): 406 mg/kg

LD50 (Rat): > 660 mg/kg

Skin corrosion/irritation

Causes skin irritation.

Components:**Oils, sesame:**

Species : Rabbit
Result : No skin irritation

N-Methyl-2-pyrrolidone:

Species : Rabbit
Method : OECD Test Guideline 404
Result : Skin irritation
Remarks : The test was conducted equivalent or similar to guideline

Ivermectin:

Species : Rabbit
Result : No skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Ivermectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.1	03.02.2025	1204361-00026	Date of first issue: 09.01.2017

Components:**Oils, sesame:**

Species	:	Rabbit
Result	:	No eye irritation

N-Methyl-2-pyrrolidone:

Species	:	Rabbit
Result	:	Irritation to eyes, reversing within 21 days
Method	:	OECD Test Guideline 405
Remarks	:	The test was conducted equivalent or similar to guideline

Ivermectin:

Species	:	Rabbit
Result	:	Mild eye irritation

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Oils, sesame:**

Test Type	:	Human repeat insult patch test (HRIPT)
Exposure routes	:	Skin contact
Result	:	negative

N-Methyl-2-pyrrolidone:

Test Type	:	Local lymph node assay (LLNA)
Exposure routes	:	Skin contact
Species	:	Mouse
Method	:	OECD Test Guideline 429
Result	:	negative
Remarks	:	Based on data from similar materials

Ivermectin:

Exposure routes	:	Dermal
Species	:	Humans
Result	:	Does not cause skin sensitisation.

Chronic toxicity**Germ cell mutagenicity**

Not classified based on available information.

Ivermectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.1	03.02.2025	1204361-00026	Date of first issue: 09.01.2017

Components:**Oils, sesame:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

N-Methyl-2-pyrrolidone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative
Remarks: The test was conducted according to guideline

Test Type: In vitro mammalian cell gene mutation test
Method: OECD Test Guideline 476
Result: negative
Remarks: The test was conducted according to guideline

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Method: OECD Test Guideline 482
Result: negative
Remarks: The test was conducted equivalent or similar to guideline

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Method: OECD Test Guideline 474
Result: negative
Remarks: The test was conducted according to guideline

Ivermectin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Test system: human diploid fibroblasts
Result: negative

Test Type: Mouse Lymphoma
Result: negative

Carcinogenicity

Not classified based on available information.

Components:**N-Methyl-2-pyrrolidone:**

Species : Rat

Ivermectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.1	03.02.2025	1204361-00026	Date of first issue: 09.01.2017

Application Route : Ingestion
Exposure time : 2 Years
Method : OECD Test Guideline 451
Result : negative
Remarks : The test was conducted according to guideline

Species : Rat
Application Route : Inhalation
Exposure time : 2 Years
Method : OECD Test Guideline 453
Result : negative
Remarks : The test was conducted equivalent or similar to guideline

Ivermectin:

Species : Rat
Application Route : Oral
NOAEL : 1.5 mg/kg body weight
Result : negative
Remarks : Based on data from similar materials

Species : Mouse
Application Route : Oral
NOAEL : 2.0 mg/kg body weight
Result : negative
Remarks : Based on data from similar materials

Reproductive toxicity

May damage the unborn child.

Components:**N-Methyl-2-pyrrolidone:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 416
Result: negative
Remarks: The test was conducted according to guideline

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 414
Result: positive
Remarks: The test was conducted according to guideline

Test Type: Fertility/early embryonic development
Species: Rat
Application Route: inhalation (vapour)
Method: OECD Test Guideline 414
Result: positive

Ivermectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
9.1	03.02.2025	1204361-00026	06.07.2024
			Date of first issue: 09.01.2017

Remarks: The test was conducted equivalent or similar to guideline

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Ingestion

Method: OECD Test Guideline 414

Result: positive

Remarks: The test was conducted equivalent or similar to guideline

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

Ivermectin:

Effects on fertility : Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 0.6 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Effects on foetal development : Test Type: Development
Species: Mouse
Application Route: Oral
Developmental Toxicity: NOAEL: 0.2 mg/kg body weight
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 0.4 mg/kg body weight

Result: Embryotoxic effects and adverse effects on the offspring were detected.

Remarks: The mechanism or mode of action may not be relevant in humans.

Test Type: Development

Species: Rabbit

Application Route: Oral

Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

STOT - single exposure

May cause respiratory irritation.

May cause damage to organs (Central nervous system) if swallowed.

Ivermectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.1	03.02.2025	1204361-00026	Date of first issue: 09.01.2017

Components:**N-Methyl-2-pyrrolidone:**

Assessment : May cause respiratory irritation.

Ivermectin:

Target Organs : Central nervous system
Assessment : Causes damage to organs.

STOT - repeated exposure

May cause damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.

Components:**Ivermectin:**

Target Organs : Central nervous system
Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****N-Methyl-2-pyrrolidone:**

Species : Rat, male
NOAEL : 169 mg/kg
LOAEL : 433 mg/kg
Application Route : Ingestion
Exposure time : 90 Days
Method : OECD Test Guideline 408
Remarks : The test was conducted according to guideline

Species : Rat
NOAEL : 0.5 mg/l
LOAEL : 1 mg/l
Application Route : inhalation (dust/mist/fume)
Exposure time : 96 Days
Method : OECD Test Guideline 413
Remarks : The test was conducted according to guideline

Species : Rabbit, male
NOAEL : 826 mg/kg
LOAEL : 1,653 mg/kg
Application Route : Skin contact
Exposure time : 20 Days
Method : OECD Test Guideline 410
Remarks : The test was conducted equivalent or similar to guideline

Ivermectin:

Ivermectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.1	03.02.2025	1204361-00026	Date of first issue: 09.01.2017

Species : Dog
NOAEL : 0.5 mg/kg
LOAEL : 1 mg/kg
Application Route : Oral
Exposure time : 14 Weeks
Target Organs : Central nervous system
Symptoms : Dilatation of the pupil, Tremors, Lack of coordination, anorexia

Species : Monkey
NOAEL : 1.2 mg/kg
Application Route : Oral
Exposure time : 2 Weeks
Remarks : No significant adverse effects were reported

Species : Rat
NOAEL : 0.4 mg/kg
LOAEL : 0.8 mg/kg
Application Route : Oral
Exposure time : 3 Months
Target Organs : spleen, Bone marrow, Kidney

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****N-Methyl-2-pyrrolidone:**

Skin contact : Symptoms: Skin irritation

Ivermectin:

Skin contact : Remarks: Can be absorbed through skin.
Eye contact : Remarks: May irritate eyes.
Ingestion : Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****N-Methyl-2-pyrrolidone:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 500 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 1,000 mg/l
Exposure time: 24 h
Method: DIN 38412
Remarks: The test was conducted according to guideline

Ivermectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
9.1	03.02.2025	1204361-00026	06.07.2024
			Date of first issue: 09.01.2017

Toxicity to algae/aquatic plants : ErC50 (Desmodesmus subspicatus (green algae)): 600.5 mg/l
Exposure time: 72 h

EC10 (Desmodesmus subspicatus (green algae)): 92.6 mg/l
Exposure time: 72 h

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 12.5 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
Remarks: The test was conducted according to guideline

Toxicity to microorganisms : EC50 (activated sludge): > 600 mg/l
Exposure time: 30 min
Method: ISO 8192
Remarks: The test was conducted according to guideline

Ivermectin:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l
Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.000025 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Persistence and degradability**Components:****Oils, sesame:**

Biodegradability : Result: Readily biodegradable.

N-Methyl-2-pyrrolidone:

Biodegradability : Result: Readily biodegradable.
Biodegradation: 73 %
Exposure time: 28 d
Method: OECD Test Guideline 301C
Remarks: The test was conducted according to guideline

Ivermectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.1	03.02.2025	1204361-00026	Date of first issue: 09.01.2017

Ivermectin:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 240 d

Bioaccumulative potential**Components:****N-Methyl-2-pyrrolidone:**

Partition coefficient: n-octanol/water : log Pow: -0.46
Method: OECD Test Guideline 107
Remarks: The test was conducted according to guideline

Ivermectin:

Bioaccumulation : Bioconcentration factor (BCF): 74

Partition coefficient: n-octanol/water : log Pow: 3.22

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(Ivermectin)
Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3082

Ivermectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.1	03.02.2025	1204361-00026	Date of first issue: 09.01.2017

Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.
(Ivermectin)

Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 964
Packing instruction (passenger aircraft) : 964
Environmentally hazardous : yes

IMDG-Code

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,
N.O.S.
(Ivermectin)
Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations**ADG**

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,
N.O.S.
(Ivermectin)
Class : 9
Packing group : III
Labels : 9
Hazchem Code : •3Z
Environmentally hazardous : yes

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture**

Therapeutic Goods (Poisons Standard) Instrument : Schedule 7 (Please use the original publication to check for specific uses, specific conditions or threshold limits that might apply for this chemical)
Prohibition/Licensing Requirements : There is no applicable prohibition, authorisation and restricted use

Ivermectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.1	03.02.2025	1204361-00026	Date of first issue: 09.01.2017

requirements, including for carcinogens referred to in Schedule 10 of the model WHS Act and Regulations.

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

SECTION 16: ANY OTHER RELEVANT INFORMATION**Further information**

Revision Date	:	03.02.2025
Sources of key data used to compile the Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/
Date format	:	dd.mm.yyyy

Full text of other abbreviations

ACGIH BEI	:	ACGIH - Biological Exposure Indices (BEI)
AU OEL	:	Australia. Workplace Exposure Standards for Airborne Contaminants.
AU OEL / TWA	:	Exposure standard - time weighted average
AU OEL / STEL	:	Exposure standard - short term exposure limit

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumu-

Ivermectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
9.1	03.02.2025	1204361-00026	Date of first issue: 09.01.2017

lative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN